Gemini gains US patent for cardiovascular risk gene:
This article was originally published in Clinica
Executive Summary
Gemini Genomics has gained a US patent for a gene that can identify a individuals with a predisposition to developing elevated levels of serum low-density lipoprotein (LDL)-cholesterol, a risk factor for cardiovascular disease. The patent is based on research conducted by scientists from the Karolinska Institute in Stockholm, Sweden, who found that specific polymorphisms in the microsomal triglyceride transfer protein (MTP) affect serum levels of LDL-cholesterol. Cambridge, UK-based Gemini has exclusive commercial rights to the gene and intends to license it to pharmaceutical and healthcare companies for the development of diagnostic and therapeutic products.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.